Enantioselective determination of ornidazole in human plasma by liquid chromatography-tandem mass spectrometry on a Chiral-AGP column

Journal of Pharmaceutical and Biomedical Analysis

Volumn 86, Issue , 2013, Pages 182-188

  Du, Jiangbo ^a   Ma, Zhiyu ^a   Zhang, Yifan ^a   Wang, Ting ^b   Chen, Xiaoyan ^a   Zhong, Dafang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Enantiomers; Enantioselective liquid chromatography tandem mass spectrometry; Ornidazole; Stereoselective pharmacokinetics

Indexed keywords

ACETIC ACID; ACETIC ACID ETHYL ESTER; AMMONIUM ACETATE; ORNIDAZOLE;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DRUG DETERMINATION; DRUG SYNTHESIS; ELECTROSPRAY; ENANTIOMER; ENANTIOSELECTIVITY; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; RACEMIC MIXTURE; TABLET; TANDEM MASS SPECTROMETRY;

APCI; AREA UNDER PLASMA CONCENTRATION-TIME CURVE TO INFINITY; AREA UNDER THE CONCENTRATION-TIME CURVE TO THE LAST MEASURABLE CONCENTRATION; ATMOSPHERIC PRESSURE CHEMICAL IONIZATION; AUC(0-T); AUC(0-∞); C(MAX); CL/F; DISTRIBUTION VOLUME; ELECTROSPRAY IONIZATION; ELIMINATION HALF-LIFE; ENANTIOMERS; ENANTIOSELECTIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; ESI; FDA; FOOD AND DRUG ADMINISTRATION; INTERNAL STANDARD; IS; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LLOQ; LOWER LIMIT OF QUANTIFICATION; MATRIX EFFECT; MAXIMUM PLASMA CONCENTRATION; ME; MEAN RESIDENCE TIME; MRM; MRT; MULTIPLE REACTION MONITORING; ORNIDAZOLE; PEAK WIDTH; QC; QUALITY CONTROL; R(S); RE; RELATIVE ERROR; RELATIVE STANDARD DEVIATION; RESOLUTION; RSD; S/N; SELECTIVE ION MONITORING; SIGNAL TO NOISE RATIO; SIM; STEREOSELECTIVE PHARMACOKINETICS; T(1/2); T(MAX); TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL BODY CLEARANCE; ULOQ; UPPER LIMIT OF QUANTIFICATION; V(D); W;

ADMINISTRATION, ORAL; CHROMATOGRAPHY, LIQUID; HUMANS; ORNIDAZOLE; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 84883416053     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.07.048     Document Type: Article

References (24)

1. Singh P., Mittal R., Sharma G.C., Singh S., Singh A. Ornidazole: comprehensive profile. Profiles Drug Subst. Excip. Relat. Method. 2003, 30:123-184.
2. Kedderis G.L., Argenbright L.S., Miwa G.T. Covalent interaction of 5-nitroimidazoles with DNA and protein in vitro: mechanism of reductive activation. Chem. Res. Toxicol. 1989, 2:146-149.
3. Muller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 1983, 93:165-171.
4. Edwards D.I. Mechanism of antimicrobial action of metronidazole. J. Antimicrob. Chemother. 1979, 5:499-502.
5. Goldstein E.J., Sutter V.L., Finegold S.M. Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538. Antimicrob. Agents Chemother. 1978, 14:609-613.
6. Wust J. Susceptibility of anaerobic bacteria to metronidazole, ornidazole, and tinidazole and routine susceptibility testing by standardized methods. Antimicrob. Agents Chemother. 1977, 11:631-637.
7. Schwartz D.E., Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 1976, 22:19-29.
8. Sun J.H., Wang Z.Q., Gu X.L., Mu R. Comparative study of ornidazole enantiomers on the toxic and side effects to central nervous system in mice. J. China Pharm. Univ. 2008, 39:343-347.
9. Wang H., Chen Y., Zhou J., Ma C., Chen Y.C., Liu X.Q. Stereoselective determination of ornidazole enantiomers in human plasma and urine samples by chiral LC: application to pharmacokinetic study. Chromatographia 2008, 67:875-881.
10. Chen Y., Liu X.Q., Zhong J., Zhao X.P., Wang Y.S., Wang G.J. Stereoselective pharmacokinetics of ornidazole after intravenous administration of individual enantiomers and the racemate. Chirality 2006, 18:799-802.
11. Bae K., Noh K., Jang K., Kim S., Yong C.S., Choi H.G., Kang J.S., Chen J., Ma E., Lee M., Shin B.S., Kwon K.I., Kang W. Analysis of enantiomers of sibutramine and its metabolites in rat plasma by liquid chromatography-mass spectrometry using a chiral stationary-phase column. J. Pharm. Biomed. Anal. 2009, 50:267-270.
12. Turnpenny P., Fraier D. Sensitive quantitation of reboxetine enantiomers in rat plasma and brain, using an optimised reverse phase chiral LC-MS/MS method. J. Pharm. Biomed. Anal. 2009, 49:133-139.
13. Kang W., Bae K., Noh K. Enantioselective determination of sibutramine and its active metabolites in human plasma. J. Pharm. Biomed. Anal. 2010, 51:264-267.
14. Kingback M., Josefsson M., Karlsson L., Ahlner J., Bengtsson F., Kugelberg F.C., Carlsson B. Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction. J. Pharm. Biomed. Anal. 2010, 53:583-590.
15. Luo W.X., Zhu L., Deng J.F., Liu A.M., Guo B., Tan W., Dai R.K. Simultaneous analysis of bambuterol and its active metabolite terbutaline enantiomers in rat plasma by chiral liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 52:227-231.
16. Meng M., Rohde L., Capka V., Carter S.J., Bennett P.K. Fast chiral chromatographic method development and validation for the quantitation of eszopiclone in human plasma using LC/MS/MS. J. Pharm. Biomed. Anal. 2010, 53:973-982.
17. Rao R.N., Kumar K.N., Shinde D.D. Determination of rat plasma levels of sertraline enantiomers using direct injection with achiral-chiral column switching by LC-ESI/MS/MS. J. Pharm. Biomed. Anal. 2010, 52:398-405.
18. Zuo Z., Wo S.K., Lo C.M., Zhou L.M., Cheng G., You J.H. Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 52:305-310.
19. Leveques A., Actis-Goretta L., Rein M.J., Williamson G., Dionisi F., Giuffrida F. UPLC-MS/MS quantification of total hesperetin and hesperetin enantiomers in biological matrices. J. Pharm. Biomed. Anal. 2012, 57:1-6.
20. Liu K., Zhong D.F., Chen X.Y. Enantioselective quantification of chiral drugs in human plasma with LC-MS/MS. Bioanalysis 2009, 1:561-576.
21. Hoffer M., Grunberg E. Synthesis and antiprotozoal activity of 1-(3-chloro-2-hydroxypropyl)-substituted nitroimidazoles. J. Med. Chem. 1974, 17:1019-1020.
22. Du J.B., You T.G., Chen X.Y., Zhong D.F. Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. Drug Metab. Dispos. 2013, 41:1306-1318.
23. US FDA Guidance for Industry: Bioanalytical Method Validation 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (accessed 06.06.13).
24. Du J.B., Deng P., Chen X.Y., Wang H.D., You T.G., Zhong D.F. Characterization of ornidazole metabolites in human bile after intraveneous doses by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry. Acta Pharma. Sin. B 2012, 2:159-167.